

# THE RISE OF TECH BIO:

Powering life science innovation

White paper

bruntwood  
SciTech

pharmaphorum™  
bringing healthcare together

# Contents

<b>Introduction</b>	<b>02</b>
<b>What is tech bio?</b>	<b>03</b>
<b>COVID-19: A turning point</b>	<b>05</b>
<b>Advancing innovation in the UK</b>	<b>08</b>
<b>Collaboration: The heart of tech bio</b>	<b>10</b>
<b>Tech bio in cell therapy</b>	<b>12</b>
<b>Tech bio in clinical trials</b>	<b>13</b>
<b>Tech bio to optimise scientific communication</b>	<b>15</b>
<b>What's next for tech bio</b>	<b>16</b>
<b>About the interviewees</b>	<b>19</b>
<b>About Bruntwood SciTech</b>	<b>20</b>



# Introduction

Amidst the life science industry's digital transformation, new and established companies have pioneered innovative ways to harness data and technology across the drug development lifecycle. From streamlining R&D workflows and collaboration with data-driven software platforms, to building tools that make the development of new therapies possible, to empowering more efficient and inclusive clinical trials, these companies are laying the foundations for a new era of life science and digital technology innovations.

The term "tech bio" describes organisations that leverage data and technology to advance life science. It's taken hold across the industry in recent years, and in the UK there's been a particular push to build and incorporate tech bio solutions into life science processes.

This white paper will explore the ways in which tech bio is transforming the life science industry. Dr Kath Mackay, Director of Life Sciences at Bruntwood SciTech, and leaders from three UK-based companies at the forefront of data-driven life science innovation - [Cellular Highways](#), [Elixir Software](#), and [NorthWest EHealth](#) - will share what tech bio means to them and how it has driven their business toward success. They'll also explore how COVID-19 sparked the sector's growth, and why the UK market is well-positioned as a hub for tech bio going forward.

[Bruntwood SciTech](#) is committed to the tech bio movement, providing cutting-edge spaces and services to life science and technology companies, and fostering innovation districts across the UK. Read on to learn how the companies who base their business at Bruntwood SciTech campuses collaborate with one another and access expertise to advance their specific areas of impact.



# What is tech bio?

According to the [UK BioIndustry Association \(BIA\)](#), tech bio combines “the ‘tech’ of technology and the ‘bio’ of biotechnology,” employing innovative techniques from both sectors to “draw insights from a wealth of data, including data concerning patients, drug molecules, healthcare infrastructure, and research and development.” While the concept of data- and technology-driven innovation in healthcare has been established in the industry, the field’s relatively new name and voice will be helpful in growing tech bio in the future.

Tech bio, therefore, seeks to identify new ways to leverage data and technology to improve, enhance, and accelerate life science processes. Because of its wide range of industry influences – pharmaceutical, biotech, pure technology, and others – tech bio also empowers entrants to the life science market who wouldn’t traditionally do business in the health and healthcare space.

“Many household-name companies that you wouldn’t consider life science or biopharma companies are now working in this area,” says Dr Mackay. “Front of mind is Amazon: with Amazon Web Services, their data platforms and analytical tools allow health and life science organisations to derive information from biological data.”

Not only does tech bio bring new companies into the healthcare market, Dr Mackay continues, it also brings new talent to the field. Individuals with expertise in data, technology, or engineering may join a tech bio company to lead key product-related functions. As a result, they can infuse their unique expertise in how to apply data and technology in other fields – perhaps finance, gaming, or retail technology – into healthcare, thereby opening doors for new innovations.

*“Tech bio approaches can help deliver personalised healthcare to more patients more quickly and at a lower cost by using data to streamline the drug discovery and development processes, as well as the implementation of novel diagnostics.”*

**Dr Kath Mackay, Director of Life Sciences, Bruntwood SciTech**



### Potential areas of impact

Given the high costs and long timelines associated with drug development and commercialisation, and the need for novel diagnostics to detect diseases at an earlier stage, there's a tremendous opportunity for tech bio to support life science companies across the medical product lifecycle. Ultimately, these new approaches will help bring new products to patients more efficiently.

"The ability to develop a drug is limited by finance and predictive tests; it can cost millions of pounds to take a drug to market and over 20 years," Dr Mackay explains. "Tech bio approaches can help deliver personalised healthcare to more patients more quickly and at a lower cost by using data to streamline the drug discovery and development processes, as well as the implementation of novel diagnostics."

During the drug discovery phase, for example, some lab bench processes are beginning to be replaced by artificial intelligence (AI) and machine learning (ML) automation. Data scientists also apply AI to unlock insights about new molecules and more complex structures. For instance, AlphaFold is a highly accurate AI system developed by DeepMind that predicts a protein's 3D structure from its amino acid sequence.

In the drug development phase, life science companies can use AI to model drug behaviour and toxicology. This helps to inform safety profiles with real-world data on the performance of a treatment. Researchers can also analyse clinical and lab data to generate insights on potential new indications for existing drugs, which helps to reduce costs and time spent during the discovery and development phases.

Within clinical trials, researchers can query patient datasets to understand which populations are most likely to respond to a new treatment based on their clinical and genetic profiles, then enrol them in the appropriate trials. This marks an important step toward achieving the aims of precision healthcare and bringing the right treatments to the right patients.

### What does tech bio mean to you?

*"Tech bio is the direct use of engineering, technology, and data approaches to biology and the development of medicines and diagnostics."*

Dr Kath Mackay, Director of Life Sciences, Bruntwood SciTech

*"It's about using physics and engineering to develop tools for life sciences, biology, therapies, and diagnostics."*

Dr Samson Rogers, Co-Founder and CEO, Cellular Highways

*"From a software point of view, it's how a software solution can enable research and take advantage of developing technologies. Where companies in the bio space were once quite siloed in their interactions, tech bio means there are no barriers to collaboration."*

Dr David Bardsley, Commercial Director, Elixir Software

*"It references the ways biotech, medical devices, and pharma mix together, particularly around using AI and technology to generate faster and better data in the interest of better personal health."*

Dr Jonathan Wogel, CEO, NorthWest EHealth

# COVID-19: A turning point

For tech bio, the COVID-19 pandemic sparked a step change in the use of data and technology at all levels of life science.

Prior to 2020, some processes within the life science sector had begun to go digital. But when COVID-19 restrictions limited face-to-face interactions and created never-before-seen urgency for new diagnostics, therapeutics, and vaccines to combat the spread of the coronavirus, the industry had to quickly pivot and make greater use of digital technologies. Pandemic-born innovations drove a new understanding of how data can be applied to healthcare.

“We saw health data being collected to understand vaccine performance, manage healthcare resources, and monitor the emergence and the spread of different variants of the COVID virus,” says Dr Mackay. For example, in the UK, researchers used data collected via the ZOE health study – a collaboration between public health researchers and the ZOE app, which help users track their responses to food and nutrition – and analysed information on COVID-19 side effects to unlock the [first understanding](#) of loss of taste and smell as a symptom of the virus.



*“The COVID vaccines are a real example of the intersection of computing power, AI technology, and the pharma and biotech industries coming together in a perfect storm to condense a ten-year drug discovery cycle to eight or nine months.”*

Dr Jonathan Wogel,  
CEO, NorthWest EHealth



## THE RISE OF TECH BIO

The development of COVID-19 vaccines was also a feat of tech bio, says Dr Jonathan Wogel, CEO of NorthWest EHealth, an organisation that specialises in the use of technology and data to make clinical trials more efficient. “The COVID vaccines are a real example of the intersection of computing power, AI technology, and the pharma and bio industries coming together in a perfect storm to condense a ten-year drug discovery cycle to eight or nine months,” says Dr Wogel.

Dr Wogel believes this success will continue to drive the usage of novel technologies in medical product development: “I think we’ll see far more leveraging of technology, and particularly IT and AI/ML, in the development of new products and therapies in the coming years.”

The increased prevalence of tech bio during the pandemic also served to increase people’s comfort and confidence with the use of data and technology in healthcare.

On an individual level, the use of health data to drive new COVID-19 insights eased worries about sharing information for the purpose of research and public health. “It doesn’t mean there weren’t concerns about ethics, privacy, and consent, but we saw that when people were clear about the purpose and potential to benefit the greater good, they were happy to participate in vaccine clinical trials and have their data used in the development process,” says Dr Mackay.

On an industry level, we also saw a shift in life sciences regarding the use of cloud-based technologies.

“There was a fear in the world about cloud computing before COVID – and a large fear in the pharmaceutical industry – that’s now become less of an issue,” says Dr David Bardsley, Commercial Director of Elixir Software, a tech company that partners with life science companies to improve scientific communications during drug discovery and development.

As a result of COVID-era tech bio successes, the field attracted interest from trade associations – which led to funding for tech bio companies. Activities such as increased recognition of the term “tech bio” by groups like BIA, combined with the convening of tech bio industry working groups, helped pave the way for emerging tech bio companies to receive the funding they need to succeed.

As the healthcare world continues to recover from COVID-19 and reflect on the learnings, challenges, and opportunities it brought about for the industry, tech bio innovations are positioned to remain a key part of the “new normal” for life sciences.

# Advancing innovation in the UK

Many people think of Silicon Valley as the centre of technology innovation or Cambridge, Massachusetts as the home of biotech, but the UK is also a veritable hub for tech bio leadership. Firstly, the UK is home to world-leading universities with dedicated research efforts in life sciences.

“The combination of academic capabilities in life science with growing digital and data capabilities will really put the UK on the global map,” says Dr Mackay.

In addition, Dr Mackay continues, the National Health Service (NHS) is unique for the UK in that it is a unified health system, which allows researchers to test and refine products at scale.

Dr Wogel describes why the UK’s regulatory environment also encourages innovation: “The MHRA’s recent policy changes show that they’re trying to encourage clinical trial delivery in the UK and create strategic data initiatives – which we’ve been lucky enough to partner on.

This will not only put the UK firmly in the centre of scientific research and clinical delivery in the next five to ten years, it’s also great for the UK economy and our patient cohorts.”

Together, the scientific leadership, forward-thinking regulatory environment, and NHS structure enable a unique opportunity for the UK. “There’s something really special about the building blocks for the life science industry that you get in the UK, along with our wider data and digital infrastructure,” says Dr Mackay.

To encourage tech bio adoption across the UK, groups like Bruntwood SciTech create innovation districts to bring forth advancements in different regions around the country. Dr Mackay explains that the campuses in each region harness the industrial, academic, and talent strengths native to each part of the UK, with their own specialties in data, digital technology, medtech, drug discovery, and life science innovation.



*“There’s something really special about the building blocks for the life science industry that you get in the UK, along with our wider data and digital infrastructure.”*

Dr Kath Mackay, Director of Life Sciences, Bruntwood SciTech

## THE RISE OF TECH BIO

With a network of over 520 companies spanning 11 districts across the UK – Manchester, Cheshire, Birmingham, Leeds, Liverpool, Cambridgeshire, and, most recently, Glasgow – Bruntwood SciTech not only provides space for companies to call home, but they support them with growth and business expertise, finance support, and connections needed to thrive and bring products to market. Companies can then collaborate to spark new ideas and solve unmet needs in life sciences.

“We work closely with cities, regions, and local authorities to create innovation districts and develop the right ecosystems for businesses to flourish. We carefully curate our campuses with the right mix of organisations and thoughtfully consider labs and facilities, shared science infrastructure and services, innovation support, finance, and talent,” Dr Mackay says. “We bring a deep understanding of the businesses that choose to locate with us, including what makes them tick and what they need to grow and scale.”



# Collaboration: The heart of tech bio

As evidenced by the composite nature of its name, collaboration is a critical piece of tech bio success.

“Tech bio itself is a collaborative effort; it brings together industries – tech, digital, and classic life science companies – that wouldn’t normally work together,” says Dr Mackay.

Leaders from three companies who host their businesses at Bruntwood SciTech campuses – Elixir Software (Alderley Park, Cheshire), NorthWest EHealth (Manchester Science Park, Manchester), and Cellular Highways, which develops therapeutic cell sorting technology to support cell therapy manufacturing (Melbourn Science Park, Cambridgeshire) – share their perspectives on why collaboration is critical to their tech bio efforts.

In the cell therapy manufacturing space:

*“Biologists, our target customers, are very collaborative people, and they’re very willing to discuss their needs. They’re open to trying new tools, and they have a hunger for new technology to solve their problems. We’re also fortunate to have the funding to be able to work with partners from an early stage, which allows us to bring our equipment to customers’ labs so they can test it.”*

Dr Samson Rogers  
Co-Founder and CEO, Cellular Highways

In the clinical trial delivery space:

*“Collaboration is our middle name. We’ve partnered with the Imperial College London and the University of Manchester on their bids for the NHS’s Strategic Data Environment, meaning that the 18 million patients they represent will be available for research in our platform between Manchester and London. It’s going to revolutionise how the UK is seen as a centre of clinical trial excellence worldwide.”*

Dr Jonathan Wogel  
CEO, NorthWest EHealth

In the drug development process optimisation space:

*“Collaboration is huge. In many cases, large life science companies cover a range of target areas and therefore aren’t as agile as smaller companies. The smaller companies can be quite focused and agile when developing new compounds, but, at some point, they need to collaborate with big players to fund taking a new entity through to a final compound.”*

Dr David Bardsley  
Commercial Director, Elixir Software

## THE RISE OF TECH BIO

To facilitate the collaboration tech bio companies need to thrive, Dr Mackay describes the framework Bruntwood SciTech employs to allow individuals from across their campuses to work together toward shared goals. Through events, targeted roundtables, mentorship, networking opportunities, and direct introductions to investors, academic institutions, and other strategic groups, Bruntwood SciTech supports business growth and helps companies attract new talent that can further enhance their business.

“Our role is to provide the infrastructure that brings together different types of businesses who work in tech and life sciences, but also to establish the right initiatives to bring them together,” Dr Mackay says. “The deliberate combination of life science and tech within the same site is really important.”



# Tech bio in cell therapy

Cell therapy, Dr Rogers explains, is the product of a decades-long scientific trend that uses engineered cells as therapeutic objects to treat diseases. This includes CAR-T therapy, in which scientists take patients' own white blood cells and program them to target and cure certain cancers and autoimmune diseases. The [NHS](#) in the UK enlists CAR-T therapies today to treat people with B cell acute lymphoblastic leukaemia, for example, and pharmaceutical companies have increased their focus on developing cell therapies.

In recent years, a rise in tech bio investment in the cell therapy space has led to new technologies that drive innovation forward.

"There has been a boom in investment in tech bio in the past 40 to 50 years, starting with the discovery of the monoclonal antibody," Dr Rogers explains. "First university researchers, then private investors became interested in new tools to support the development of therapeutics and diagnostics based on advances in science. From there, people with other skills – such as physical sciences

and engineering – were drawn to the field to solve problems, such as measurement or manipulation of cells and bio molecules."

For drug developers, the challenge with creating cell therapies lies in manufacturing. Some of the necessary cells are rare, so it's difficult to identify and isolate them from other cells based on their molecular makeup. Scientists must separate the target cells from others at a high threshold of purity and yield, but the technologies to support this effort are lacking.

Cellular Highways takes a tech bio approach to filling this gap with its Highway1 technology, which separates cells in a safe, sterile, fast, and scalable way. By collaborating with pharmaceutical manufacturers, Cellular Highways helps developers sort the cells they need to develop innovative therapies for patients in ways they couldn't access before.

"We've enabled a way to separate and manipulate these cells, which has made some approaches possible that scientists couldn't do before," Dr Rogers says. "Treg therapies

are one example; they're white blood cells that turn off the immune system, and they can be interesting for cures for immune and autoimmune diseases. The only way to make these is with a cell sorter. Today, several companies use sterile fluorescence-activated cell sorters in their clinical trials to develop these therapies. We enable these companies to get their science closer to patients."

While cell sorting technologies are still in their early days, clinical trials are underway to validate approaches like Cellular Highways'. Dr Rogers is optimistic that their cell sorter and other tech bio-driven advances will continue to support scientific innovation and development for future cell therapies.

"The future of cell therapy is difficult to predict, and I think it will take decades to see how the various approaches unfold and which win over others," Dr Rogers says. "Our technology is useful for a number of cell sorting methodologies. It's an important, general tool that enables these therapies to become a reality."



*"Our technology is useful for a number of cell sorting methodologies. It's an important, general tool that enables these therapies to become a reality."*

Dr Samson Rogers, Co-Founder and CEO, Cellular Highways

# Tech bio in clinical trials

The key points of the argument for clinical trial reform are widely known in the life science industry: they're too expensive, too time consuming, and not diverse enough to represent real-world populations. By utilising tech bio techniques in clinical studies – such as with decentralised trials, which use data to identify the right patients for trials then enable remote participation through technology – trial sponsors can make studies more efficient, effective, and convenient for patients.

NorthWest EHealth is one company developing a tech bio solution to the clinical trials problem: a clinical trials delivery software platform that facilitates the use of healthcare data in decentralised trial design.

“We design trials with pharmaceutical and biotech companies globally to help them bring better therapies to market faster for patients that really need them,” Dr Wogel says.

One feature of NorthWest EHealth's system is the FARSITE platform, which leverages large healthcare datasets to accelerate patient recruitment in clinical trials. Rather than being restricted to patients who live locally to trial sites, researchers can analyse data to identify patients for their studies across wide geographies and from demographically representative populations. The process of recruiting patients with data is also faster than the traditional model: “Using our technology we can model feasibility – which used to take weeks and months – in just minutes and hours, then understand the best ways to design clinical trials and recruit the right patients,” Dr Wogel says.



*“Using our technology we can model feasibility – which used to take weeks and months – in just minutes and hours, then understand the best ways to design clinical trials and recruit the right patients.”*

Dr Jonathan Wogel,  
CEO, NorthWest EHealth

## THE RISE OF TECH BIO

Another challenge of traditional clinical trials pertains to data collection. In the past, patients would have to travel to a clinical site for clinicians to collect data on their experience with the trial drug. These meetings were not only inconvenient for patients to attend – for example, if they had to drive long distances, arrange childcare, or miss work to attend an appointment – they created inherent lags and gaps in data. Patients were asked to recall details about their health since the last time they saw a provider, perhaps at the six-month mark after the trial commenced. Naturally, they may have forgotten some events, and potentially important data points wouldn't be recorded in the safety profile of the trial drug.

Since the early days of the industry's digital transformation, companies have assessed tech bio approaches to fill gaps in data collection between patients' and providers' in-person interactions. And with ConneXon, NorthWest EHealth's electronic data capture system, trial sponsors can connect and ingest data from a range of sources including wearable devices, NHS records, and others to enable real-time reporting on safety events during

clinical studies. ConneXon also allows clinical trial and endpoint data to be collected directly from the source, giving broader and more accurate data while eliminating the need for most transcription. Through the combination of safety monitoring and direct-from-source data, ConneXon makes pragmatic trials a reality.

Dr Wogel explains how this could work in practice: "Imagine you go to the doctor's office and are dosed for a trial on Monday in Manchester, then when you're in London on Wednesday you feel sick and go to A&E. That information gets captured on your healthcare record, fed back into ConneXon, reported back to the sponsor, and relayed back to the doctor that administered the drug within 24 hours."

This tech bio innovation enables better and safer trial experiences for patients.

"Patient safety is better than ever before using AI and ML to power software to give better outcomes," Dr Wogel says. "It also helps drug companies create better endpoints that matter to patients."



*"Patient safety is better than ever before using AI and ML to power software to give better outcomes. It also helps drug companies create better endpoints that matter to patients."*

Dr Jonathan Wogel,  
CEO, NorthWest EHealth

# Tech bio to optimise scientific communication

The drug discovery and development process involves many teams and organisations who need to work in close collaboration to move a new molecule from the wet lab through to trials and, eventually, to patients. But communication across the various phases of discovery and development has, to date, remained siloed.

For example, Dr Bardsley explains, one team may design a chemical compound, but need to work with another to have it made into a potential drug candidate. During that process, the product would be designed, requested, made, purified, and shipped. Throughout all this activity, different teams record data in PowerPoints, Excel spreadsheets, and Word documents, then send the files via email to their collaborators. This is an imperfect system – critical information could be lost along the way.

Enter: tech bio. Elixir Software's iTrax cloud-based system is designed to improve communication between scientists through the drug discovery and development cycles. Rather than replacing teams' existing systems, iTrax integrates with databases to enhance operations. The technology also solves challenges with outdated information and timeline management by making all information relevant to development teams live on the cloud.

"With iTraX, everything is live," Dr Bardsley says. "I could log in at any time to see progress on projects in other sites, or even know when people are off ill or haven't made progress in a few days. It's brought a real way of collaborating."

Data security is another key topic in the pharmaceutical industry's digital transformation: how can companies ensure only the relevant people can access project updates? iTrax enables version control and

permission settings, so collaborators only access the information that's relevant to their work. This ensures security, especially with highly sensitive patient information. What's more, the cloud-based format makes systems easier to recover in the case of cyberattacks: "If your on-prem database was attacked, your complete recovery from the cyber-attack could be three to six months. If it's on the cloud, you can expect this to be reduced to a matter of hours," says Dr Bardsley.

Ultimately, by enabling more effective use of resources in the drug development process with tech bio approaches, Elixir Software hope to improve transparency, speed, and collaboration in the clinical development process.

"We strive for all-around efficiency," Dr Bardsley says. "We don't want to replace a company's database, we want to enable more efficient use of data and time."



*"We strive for all-around efficiency. We don't want to replace a company's database, we want to enable more efficient use of data and time."*

Dr David Bardsley, Commercial Director, Elixir Software

## What's next for tech bio

Tech bio has the potential to impact many sectors of the life science industry, and the focus now needs to be on building the processes and capabilities needed to scale the adoption of novel approaches and achieve its transformative promise in the UK. Dr Mackay references a need for additional regulatory considerations around the use of data in healthcare processes and decision-making, while Dr Wogel mentions a need for more data capabilities within the NHS.

“The NHS as an institution needs to have a more open mind about collaborating with industry on big data initiatives,” Dr Wogel says. “I think that would lead to a step change in how the UK is perceived as a clinical research port of call, and it would also help us deliver better therapies faster to the right patients.” He also notes a need for improved interoperability across NHS datasets, particularly to fill information gaps as patients travel between primary and specialist care.



## THE RISE OF TECH BIO

As tech bio continues to grow in influence across healthcare, there are exciting times ahead and many spaces to watch for further advancements. Our interviewees shared what they're most interested to see in the years to come:

### What tech bio trends are you watching?

#### Early diagnosis

*"For me, what's really interesting is the ability to use digital and tech bio approaches in the diagnosis and particularly the early diagnosis of disease, including cancer, even before symptoms appear. This is currently an unmet need, and the earlier you diagnose an illness, the more treatment options you have available."*

Dr Kath Mackay, Director of Life Sciences, Bruntwood SciTech

#### Gene editing with CAR-T cells

*"The ultimate potential is to make a therapy that's more effective and easier to manufacture based on more effective cells that can be administered in lower doses."*

Dr Samson Rogers  
Co-Founder and CEO, Cellular Highways

#### AI and ML

*"For me, the buzzwords are AI, ML, and natural language processing applied in biotechnology. That will unlock the art of the possible in the next 25 years."*

Dr Jonathan Wogel  
CEO, NorthWest EHealth

#### Advancements in cloud computing

*"We are excited to see cloud computing go from strength to strength, because if it does, it will ease the load problem and bring down costs."*

Dr David Bardsley  
Commercial Director, Elixir Software

## THE RISE OF TECH BIO

As organisations across the spectrum of tech bio continue to develop novel ways to use data and technology in life sciences, the industry can expect to see even more innovations and improvements in the future. Whether through systems that enable more streamlined workflows, tools that power new discoveries, or initiatives that involve more diverse populations in the clinical research process, collaboration will be key to unlocking the next generation of technologies that bring more effective treatments to the right patients, faster.



# About the interviewees



**Dr Kath Mackay,  
Director of Life  
Sciences, Bruntwood  
SciTech**

Dr Kath Mackay is Director of Life Sciences at Bruntwood SciTech - a 50:50 JV between leading property developer Bruntwood and Legal & General - the UK's leading provider of science and technology focused property assets. She has a keen interest in growing the life science industry, and businesses and infrastructure within the sector, ensuring the UK is the best place to establish and grow a life science organisation.

Dr Mackay joined Bruntwood SciTech from the executive board of Innovate UK where she led the team responsible for growing and scaling businesses working in the biomedical, health, agriculture, and food sectors, creating and delivering a £700m portfolio of infrastructure, Catapults, and grant and loan investments. Dr Mackay is also Non-Executive Director of the Northern Health Science Alliance, the North of England's health partnership, UKRI's National Biofilms Innovation Centre, and Cheshire and Warrington Local Enterprise Partnership.



**Dr David Bardsley,  
Commercial Director,  
Elixir Software**

Dr David Bardsley combines his role as Commercial Director with the same position at Cresset. Through his global experience and direct interactions with people across industry, he is always seeking ways to serve customers better.

His fundamental rule is to listen to the customer in order to discover and understand their needs; he has extensive commercial experience with software and technology solutions in the scientific market.

Dr Bardsley has been responsible for business development and strategic commercial growth at Cresset and also previously at Symyx Technologies and CambridgeSoft. Dr Bardsley has a PhD and BSc in microbiology from the University of Wales, Cardiff.



**Dr Samson Rogers,  
Co-Founder and CEO,  
Cellular Highways**

Dr Samson Rogers leads Cellular Highways, a spin-out from TTP plc, developing a new cell sorter technology. Major applications in biotech across research, therapeutics, and diagnostics lack a method for fast, sterile, and scalable cell sorting. Cellular Highways' proprietary technology, VACS, leads the field, offering the required speed, cytometry performance, sterility, automation, and scalability to sort one billion cells per hour.

Dr Rogers's background is as a scientist, inventor, and entrepreneur, with a research background in biological physics of molecules and cells. He has experience developing technology on a range of devices, and he previously founded two start-ups.



**Dr Jonathan Wogel,  
CEO, NorthWest  
EHealth**

Dr Wogel has over 35 years of global pharma, device & biotech M&A, JV licensing, and scale up experience, with over 27 years as an expat. He has developed over £5bn in M&A deals for private and PE backed businesses and launched/licenced over 50 products globally.

More recently, Dr Wogel has focused on helping SMEs and startups with seed/Series A, B, and Angel/PE based fundraising by developing and implementing business and commercial strategies to drive scale.

Dr Wogel has an undergraduate degree in biochemistry and holds an MBA, MPH, and PhD in health economics. He is also the Executive Chair & a Director of Zentraxa, a biomaterials spin out from the University of Bristol.

# About Bruntwood SciTech

Bruntwood SciTech connects the UK's most ambitious cities, regions, and science and technology communities through extensive opportunities for collaboration and access to an extensive public, private, academic, and clinical partner network. A 50/50 joint venture between Bruntwood and Legal & General, Bruntwood SciTech is the UK's leading property provider dedicated to the growth of the science and technology sector, supporting businesses to form, scale, and grow.

Bruntwood SciTech provides science and tech businesses with high quality office and laboratory space across some of the UK's most thriving innovation regions, including Manchester, Birmingham, Leeds, Liverpool, Cambridgeshire, Cheshire, and Glasgow. They also deliver a range of scientific services, and tailored business support offering unrivalled access to finance, talent, markets, and mentorship. Learn more at [bruntwood.co.uk/scitech/](https://bruntwood.co.uk/scitech/).



bruntwood  
SciTech

pharmaphorum™  
bringing healthcare together